Pfizer-BioNTech’s vaccine gets slightly weaker over time, company data shows, but remains strong in preventing severe disease.
With cases rising in the U.S., the findings may influence the Biden administration’s deliberations about delivering a booster shot.
View original article
Contributor: Carl Zimmer and Sharon LaFraniere
